Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Immutep Limited (IMMP) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Immutep Limited ("Immutep" or "the Company") (NASDAQ:IMMP). Investors who purchased Immutep securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IMMP.

Immutep Investigation Details

On March 13, 2026, Immutep issued a press release "announcing that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (‘efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According to the press release, "based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility" and that, accordingly, "enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations." Following this news, Immutep's American Depositary Receipt ("ADR") price fell $2.27 per ADR, or 82.44%, to close at $0.48 per ADR on March 13, 2026.

What's Next for Immutep Investors?

If you are aware of any facts relating to this investigation or purchased Immutep securities, you can assist this investigation by visiting the firm's site: bgandg.com/IMMP. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Immutep Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Immutep Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC